ArticleJournal of clinical immunology2009
IL-2, IFN-gamma, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis.
Article in Journal of clinical immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Synergistic myelin regenerative, immunomodulatory and anti-inflammatory effects of vanillin and adipose derived stem cells in cuprizone animal model of multiple sclerosis.Iranian journal of basic medical sciences · 2026Article
- Decoding the Potential Impact of Plasma hsa-miR-24-3p and hsa-miR-181 d-3p Expression, Plasma IFN-γ Levels, and IFNG rs2069727 T/C Genetic Variant on Multiple Sclerosis Risk and Glatiramer Acetate Treatment.Molecular neurobiology · 2025Article
- Causal association between the peripheral immunity and the risk and disease severity of multiple sclerosis.Frontiers in immunology · 2024Article
- The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.Journal of translational autoimmunity · 2021Review
- Increased IL-2 and Reduced TGF-β Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis.Biomedicines · 2020Article
- Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.Cellular and molecular neurobiology · 2020Review
- Age and sex-adjusted incidence and yearly prevalence of multiple sclerosis (MS) in Mazandaran province, Iran: An 11-years study.PloS one · 2020Article
- Association of genetic polymorphisms in interferon-γ, interleukin-6 and transforming growth factor-β1 gene with oral lichen planus susceptibility.BMC oral health · 2016Article
- Natural Killer Cell Subsets and IL-2, IL-15, and IL-18 Genes Expressions in Chronic Kidney Allograft Dysfunction and Graft Function in Kidney Allograft Recipients.International journal of organ transplantation medicine · 2016Article
- Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis.Molecular biology reports · 2014Article
- The association of -475 and -631 interleukin-2 gene polymorphism with multiple sclerosis in Iranian patients.Cell journal · 2013Article
- Interactions of interleukin-12A and interleukin-12B polymorphisms on the risk of intracranial aneurysm.Molecular biology reports · 2012Article
- Article
- Lack of Association between Interleukin 12 C(-1188)A Polymorphism and Irritable Bowel Syndrome.Avicenna journal of medical biotechnology · 2011Article
- Th17 cells in autoimmune demyelinating disease.Seminars in immunopathology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) is a multifactorial disease. Positive genetic background could predispose individuals to this chronic disabling disease. In order to investigate the role of some proinflammatory cytokines (interleukin (IL)-2, IL-12, and interferon-gamma (IFN-gamma)) as a risk factor for MS, this study was performed.
methodsTwo hundred and eleven patients with relapsing-remitting form of MS were enrolled in this study and compared with 359 healthy individuals. Using polymerase chain reaction based on sequence-specific primer method, the cytokine genes were amplified, and alleles and genotypes were detected on gel electrophoresis.
resultsSignificant increases for IFN-gamma AT (+874) genotype (54.5% vs. 37.8%, p = 0.0002) and IL-12 AA (-1188) genotype (60.8% vs. 49.7%, p = 0.014) were found in MS patients in comparison with healthy controls. A significant decrease in IFN-gamma TT (+874) genotype (17.7% vs. 27.5%, p = 0.01) and IL-12 CA (-1188) genotype (30.9% vs. 45%, p = 0.001) in MS patients was also detected. No significant differences of IL-2 G/T (-330) and IL-2 G/T (+166) in alleles and genotypes were observed between MS patients and normal subjects.
conclusionsIt could be suggested that the genetic variation in IL-12 A/C (-1188) and IFN-gamma A/T (+874) cytokine genes could be risk factors for MS patients.
Indexed as
Identifiers
19543959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.